Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

159 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictive value of the ERCC1 expression for treatment response and survival in advanced gastric cancer patients receiving cisplatin-based first-line chemotherapy.
Yun J, Kim KM, Kim ST, Kim JH, Kim JA, Kong JH, Lee SH, Won YW, Sun JM, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK. Yun J, et al. Among authors: kong jh. Cancer Res Treat. 2010 Jun;42(2):101-6. doi: 10.4143/crt.2010.42.2.101. Epub 2010 Jun 30. Cancer Res Treat. 2010. PMID: 20622964 Free PMC article.
Matrix metalloproteinase-1 expression can be upregulated through mitogen-activated protein kinase pathway under the influence of human epidermal growth factor receptor 2 synergized with estrogen receptor.
Jung HH, Park YH, Jun HJ, Kong J, Kim JH, Kim JA, Yun J, Sun JM, Won YW, Lee S, Kim ST, Ahn JS, Im YH. Jung HH, et al. Among authors: kong j. Mol Cancer Res. 2010 Jul;8(7):1037-47. doi: 10.1158/1541-7786.MCR-09-0469. Epub 2010 Jun 15. Mol Cancer Res. 2010. PMID: 20551150 Free article.
Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin's Lymphoma: A Multicenter Randomized Phase II Study bythe Consortium for Improving Survival of Lymphoma (CISL).
Kim KH, Lee JH, Lee M, Kim HG, Do YR, Park Y, Oh SY, Shin HJ, Kim WS, Park SK, Kong JH, Park MR, Yang DH, Kwak JY, Kang HJ, Mun YC, Won JH. Kim KH, et al. Among authors: kong jh. Cancer Res Treat. 2023 Jan;55(1):304-313. doi: 10.4143/crt.2022.004. Epub 2022 Mar 30. Cancer Res Treat. 2023. PMID: 35381164 Free PMC article. Clinical Trial.
Early dose reduction of dasatinib does not compromise clinical outcomes in patients with chronic myeloid leukemia: A comparative analysis of two prospective trials.
Shin DY, Park S, Jang E, Kong JH, Won YW, Oh S, Choi Y, Kim JA, Lee SW, Mun YC, Kim H, Kim SH, Rok Do Y, Kwak JY, Kim HJ, Zang DY, Lim SN, Lee WS, Kim DW. Shin DY, et al. Among authors: kong jh. Leuk Res. 2024 Aug;143:107542. doi: 10.1016/j.leukres.2024.107542. Epub 2024 Jun 17. Leuk Res. 2024. PMID: 38924942
159 results